EP0675723A4 - Bisphosphonate/estrogen therapy for treating and preventing bone loss. - Google Patents

Bisphosphonate/estrogen therapy for treating and preventing bone loss.

Info

Publication number
EP0675723A4
EP0675723A4 EP94905419A EP94905419A EP0675723A4 EP 0675723 A4 EP0675723 A4 EP 0675723A4 EP 94905419 A EP94905419 A EP 94905419A EP 94905419 A EP94905419 A EP 94905419A EP 0675723 A4 EP0675723 A4 EP 0675723A4
Authority
EP
European Patent Office
Prior art keywords
bisphosphonate
treating
bone loss
preventing bone
estrogen therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP94905419A
Other languages
German (de)
French (fr)
Other versions
EP0675723A1 (en
Inventor
Donna T Whiteford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0675723A1 publication Critical patent/EP0675723A1/en
Publication of EP0675723A4 publication Critical patent/EP0675723A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP94905419A 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss. Ceased EP0675723A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99641892A 1992-12-23 1992-12-23
PCT/US1993/012302 WO1994014455A1 (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss
US996418 1997-12-22

Publications (2)

Publication Number Publication Date
EP0675723A1 EP0675723A1 (en) 1995-10-11
EP0675723A4 true EP0675723A4 (en) 1998-08-05

Family

ID=25542895

Family Applications (1)

Application Number Title Priority Date Filing Date
EP94905419A Ceased EP0675723A4 (en) 1992-12-23 1993-12-17 Bisphosphonate/estrogen therapy for treating and preventing bone loss.

Country Status (5)

Country Link
EP (1) EP0675723A4 (en)
JP (1) JPH08505142A (en)
AU (1) AU5953894A (en)
CA (1) CA2151240A1 (en)
WO (1) WO1994014455A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL173026B1 (en) * 1993-05-15 1998-01-30 Boehringer Mannheim Gmbh Tablet of improved biological accessibility, containing dichloromethylene biphosphonic acid as active substance
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
ZA956029B (en) * 1994-07-22 1997-01-20 Lilly Co Eli Combination treatment for inhibiting bone loss
US5780455A (en) * 1994-08-24 1998-07-14 Merck & Co., Inc. Intravenous alendronate formulations
AU713824B2 (en) * 1995-05-12 1999-12-09 Merck Sharp & Dohme Corp. Prevention of tooth loss by the administration of alendronate or its salts
US5545635A (en) * 1995-05-23 1996-08-13 Eli Lilly And Company Inhibiting bone loss with equilenin
US5616571A (en) * 1995-06-06 1997-04-01 Merck & Co., Inc. Bisphosphonates prevent bone loss associated with immunosuppressive therapy
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
IL120265A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis - polyphosphonates or progestins and estrogen agonists
US5853759A (en) * 1996-05-17 1998-12-29 Merck & Co.. Inc. Effervescent alendronate formulation
DE69726879T2 (en) * 1996-05-17 2004-10-14 Merck & Co., Inc. BIPHOSPHONATE FORMULATION WITH EFFECT
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
EP0949928A4 (en) * 1996-11-25 2000-09-13 Merck & Co Inc Androgenic and bisphosphonic agents coadministered to treat diseases
DE19719680A1 (en) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Use of diphosphonic acids for the preventive treatment of long-term consequences of bladder enlargement or replacement
US6555529B1 (en) * 1997-12-25 2003-04-29 Toray Industries, Inc. Remedies for intramedullary diseases
PT1135140E (en) * 1998-12-04 2005-10-31 Roche Diagnostics Gmbh UTILIZATION OF IBANDRONATO FOR THE PROMOTION OF ENDOPROTESES OSSEA INTEGRATION
WO2000064516A1 (en) * 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
FR2803521B1 (en) 2000-01-12 2002-10-25 Ceva Sante Animale USE OF TILUDRONIC ACID AND ITS DERIVATIVES IN POULTRY FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR PREVENTING AND TREATING OSTEOPOROSIS
CA2435552C (en) * 2001-02-06 2010-04-27 The Royal Alexandra Hospital For Children A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
US20040157798A1 (en) * 2001-04-03 2004-08-12 Little David Graham Drug for use in bone grafting
AUPR553701A0 (en) * 2001-06-07 2001-07-12 Royal Alexandra Hospital For Children, The A device for the delivery of a drug to a fractured bone
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
WO2003057136A2 (en) 2001-12-24 2003-07-17 Teva Pharmaceutical Industries Ltd. Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material, and process and tooling for producing it
US7488496B2 (en) 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
EP1508343B1 (en) * 2003-08-21 2015-11-04 AddBIO AB Bisphosponate coated implant device and method therefor
US8940320B2 (en) 2005-10-27 2015-01-27 Thommen Medical Ag Dental implant and production method for said implant
US8882740B2 (en) 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (en) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NEW 17-β-OESTRADIOL DERIVATIVES, A METHOD OF PREPARING THEM, AND DRUGS CONTAINING THEM
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
WO1992014474A1 (en) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Methods for the treatment of osteoporosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623397A1 (en) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh NEW DIPHOSPHONIC ACID DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992005187A1 (en) * 1990-09-18 1992-04-02 Boehringer Mannheim Gmbh NEW 17-β-OESTRADIOL DERIVATIVES, A METHOD OF PREPARING THEM, AND DRUGS CONTAINING THEM
EP0496520A1 (en) * 1991-01-22 1992-07-29 Merck & Co. Inc. Novel bone acting agents
WO1992014474A1 (en) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Methods for the treatment of osteoporosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CIMINERA N. ET AL: "Studio Comparativo degli effeti di estrogeni e difosfonati sulla perdita ossea postmenopausale", ANN. OSTET. GINECOL. MED. PERINAT., vol. 113, no. 5, 1992, pages 232 - 237, XP002064831 *
See also references of WO9414455A1 *

Also Published As

Publication number Publication date
AU5953894A (en) 1994-07-19
EP0675723A1 (en) 1995-10-11
JPH08505142A (en) 1996-06-04
WO1994014455A1 (en) 1994-07-07
CA2151240A1 (en) 1994-07-07

Similar Documents

Publication Publication Date Title
EP0675723A4 (en) Bisphosphonate/estrogen therapy for treating and preventing bone loss.
IL112455A0 (en) Combination treatment for osteoporosis
IL115310A0 (en) Combination therapy for hypercholesterolemia
EP0589252A3 (en) Fibrillation induction method for implantable devices.
AP2002002661A0 (en) Combination therapy for oesteoporosis
ZA958688B (en) Methods for treating resistant tumors
IL122149A0 (en) Bisphosphonates preventing bone loss associated with immunosuppressive therapy
GB2296108B (en) Tractor and machine combination and control system therefor
GB9808936D0 (en) Combination therapy for the prevention and treatment of osteoporosis
GB9303210D0 (en) Cancer treatment
GB9215042D0 (en) Microwave treatment apparatus
HU9302183D0 (en) Medical preparatives for preventing and treating osteoporises after menopausa
IL108197A0 (en) Pharmaceutical composition for preventing or treating arterioscleriosis
EP0650372A4 (en) Compounds for cancer imaging and therapy.
HU9402578D0 (en) Medicament for treating or preventing cerebrovascular diseases
GB9308802D0 (en) Treatment
GB9315275D0 (en) Formulation for treating silage
GB9217124D0 (en) Medical treatment
EP0839032A4 (en) Hydroxyl ions as unique therapeutic agents and compounds that modulate ions, compounds
PL320564A1 (en) Therapeutic set for treating osteoporosis
PL331283A1 (en) Preparation for treating and/or preventing stupefaction
HK1021946A1 (en) Electromagnetic therapeutic treatment device.
GB9201630D0 (en) Off-gas treatment
EP0662782A4 (en) Pp14-based therapy.
GB2268409B (en) Bone implant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950724

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19980619

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 19981008

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20031106

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1009249

Country of ref document: HK